EULAR Congress 2026

RA Patients Face Elevated Fracture Risk: EULAR 2026 Highlights

Rheumatoid arthritis (RA) significantly increases fracture risk beyond traditional factors. EULAR 2026 data underscores the need for early bone health assessment.

TLR7/8 Inhibition Offers New Lupus Perspective at EULAR 2026

New insights into systemic lupus erythematosus (SLE) pathogenesis highlight the role of TLR7/8, with emerging therapeutic strategies.

B-Cell Dysregulation Targeted Upstream in Primary Sjögren Disease

New research presented at EULAR 2026 explores upstream B-cell targeting to address primary Sjögren disease pathology, focusing on early intervention.

XLH Management: Rheumatology Must Adapt at EULAR 2026

Current rheumatology approaches for rare bone diseases like X-linked hypophosphatemia (XLH) require re-evaluation. EULAR 2026 presents an opportunity to integrate multidisciplinary care models.

Systemic Sclerosis: EULAR 2026 Highlights Diagnosis, Prognosis

EULAR 2026 addressed evolving concepts in systemic sclerosis, focusing on refined diagnostic criteria and prognostic indicators for earlier intervention.

Salivary Galectin-9 Elevated in Primary Sjögren's, Lacks Disease Activity Correlation

Salivary galectin-9 levels are elevated in primary Sjögren's disease but do not correlate with disease activity or symptoms.

CD19+ B-Cell Targeting Shows Efficacy in IgG4-RD Management

Targeting CD19+ B-cells offers a corticosteroid-sparing strategy for IgG4-Related Disease, addressing relapse rates and long-term toxicity.

Early Intervention in SLE/LN Reduces Long-Term Damage

Acting early in systemic lupus erythematosus (SLE) and lupus nephritis (LN) is critical for preventing irreversible organ damage and improving patient outcomes.

Early AxSpA Diagnosis: Case-Based Discussion at EULAR 2026

A EULAR 2026 session addressed the diagnostic delay in axial spondyloarthritis, highlighting the need for improved GP recognition and referral pathways.

EGPA: Early Recognition & Targeted Intervention Improve Outcomes

Eosinophilic granulomatosis with polyangiitis (EGPA) presents diagnostic challenges; timely intervention is critical for improved patient outcomes.

ANCA Vasculitis: Evolving Strategies Target Remission & Relapse Prevention

New strategies in ANCA-associated vasculitis (GPA/MPA) focus on achieving sustained remission and preventing relapse with targeted therapies.

Obesity Management Improves Psoriatic Disease Outcomes

Addressing obesity in psoriatic disease patients improves dermatological and musculoskeletal outcomes, highlighting the need for integrated care strategies.

RA Treatment Optimisation: Applying Two Decades of Progress

EULAR 2026 highlights the evolution of rheumatoid arthritis management, emphasising early, aggressive intervention and treat-to-target strategies.

SLE Pathophysiology Advances Inform Future Precision Care at EULAR 2026

New insights into systemic lupus erythematosus (SLE) pathophysiology presented at EULAR 2026 highlight pathways for targeted therapies and precision medicine.

Multidisciplinary Approach Improves Autoimmune ILD Management

A collaborative model involving rheumatology, radiology, and pulmonology is essential for effective autoimmune interstitial lung disease (ILD) care.

Optimising PsA and axSpA Treatment: EULAR 2026 Focuses on Early Intervention

EULAR 2026 will address the critical need for early, targeted intervention in psoriatic arthritis and axial spondyloarthritis to improve patient outcomes.

CAR T Cell Therapy Shows Efficacy in Autoimmune Diseases at EULAR 2026

CAR T cell therapy demonstrates promising efficacy in refractory autoimmune diseases, offering a potential new therapeutic avenue for severe cases.

Rapid SLE Control Prevents Organ Damage: EULAR 2026 Focus

EULAR 2026 highlights the critical role of rapid disease control in systemic lupus erythematosus (SLE) to mitigate irreversible organ damage.

SpA Remission: Clinical Symptoms vs. Subclinical Inflammation at EULAR 2026

EULAR 2026 highlights a critical disconnect in spondyloarthritis (SpA) remission, where patient-reported symptom resolution often belies persistent subclinical inflammation.

EULAR 2026: Methotrexate Remains Cornerstone in RA First-Line

EULAR 2026 reaffirms methotrexate's central role in first-line rheumatoid arthritis therapy, with new data on optimal dosing and combination strategies.

Autoantibodies: Hidden Drivers of Autoimmune Rheumatic Diseases

EULAR 2026 highlights the role of autoantibodies in autoimmune rheumatic diseases, offering insights into early diagnosis and targeted therapies.

CAR T Cell Therapy Shows Promise in SLE and SSc Immune Reset

CAR T cell therapy is emerging as a potential immune reset strategy for severe systemic lupus erythematosus and systemic sclerosis, offering a new therapeutic avenue.

VEXAS Syndrome: Expert Consensus on Multidisciplinary Care at EULAR 2026

EULAR 2026 discussions highlight the need for integrated, multidisciplinary approaches to VEXAS syndrome, focusing on early diagnosis and targeted management.

Sjögren’s Disease: Targeting Underlying Activity Beyond Symptoms

New insights at EULAR 2026 highlight the need to address objective disease activity in Sjögren’s, moving beyond symptomatic management.

Lupus Management: Progress and Persistent Challenges at EULAR 2026

Systemic lupus erythematosus (SLE) remains a complex autoimmune disease with significant unmet needs despite therapeutic advancements. EULAR 2026 will review current progress and future directions.

EULAR 2026: Polymyalgia Rheumatica Guidelines Incorporate RWE

EULAR 2026 guidelines for polymyalgia rheumatica (PMR) integrate real-world evidence (RWE), refining diagnostic and treatment algorithms.

RA Care: Navigating Treatment Choices at EULAR 2026

Rheumatoid arthritis management requires precise treatment selection. EULAR 2026 highlights the ongoing challenge of optimising therapy.

EULAR 2026: Psoriatic Disease Spectrum Highlights

EULAR 2026 presentations address the broad clinical manifestations of psoriatic disease, emphasizing early diagnosis and tailored management across its diverse phenotypes.

Early SLE Disease Control: Targeting IFN Pathway at EULAR 2026

Achieving early disease control in systemic lupus erythematosus (SLE) is critical for preventing organ damage. Targeting the interferon (IFN) pathway offers a precise therapeutic strategy.

Multidisciplinary Care Improves Spondyloarthritis Outcomes

A multidisciplinary approach to spondyloarthritis, addressing both articular and extra-musculoskeletal manifestations, improves patient outcomes.

EULAR 2026: Earlier AxSpA Recognition Improves Disease Burden

New insights from EULAR 2026 highlight the critical role of early diagnosis and optimised management strategies in reducing the disease burden of axial spondyloarthritis (axSpA).

Treat-to-Target in SLE: Balancing Burden, Benefit, and Risk

Treat-to-target strategies in Systemic Lupus Erythematosus (SLE) aim for optimal disease control but introduce patient burden and potential risks.

Early Intervention Crucial for Inflammatory Joint Disease, Osteoporosis

EULAR 2026 highlights the imperative of early diagnosis and intervention in inflammatory joint diseases and osteoporosis to prevent irreversible damage.

Early ILD Recognition in SARD/SSc: Drivers of Progression and Workflow Solutions

Early identification of interstitial lung disease (ILD) in systemic autoimmune rheumatic diseases (SARD) and systemic sclerosis (SSc) is critical.

Immuno-Fibrotic Crosstalk: A New Target in Rheumatology

EULAR 2026 will address the complex interplay between immune and fibrotic pathways in rheumatic diseases, offering new therapeutic avenues.